| 3 Months Avg. Volume: 113.28K 1 Month Avg. Volume: 215.17K 10 Days Avg. Volume: 108.26K 5 Days Avg. Volume: 49.23K |
| Company Address 6121 Hollis Street Emeryville, CA 94608 United States |
PSD Comments Right now, BTIM is one of the only penny stocks with increasing volume over the past few months that is moving up. The company, although tiny, has been around for a while and the stock has a long history of surprising stability given it's market cap. The stock hit a high of around 20 dollars in the mid nineties, and hit rock bottom at around 50 cents more recently. The stock has been on a steady climb all year long. As with most small Bio-tech startups, this company also has a long history of losing money. This can be overlooked for several reasons, the first one being that our intentions for a trade are not long term. Additionally, the norm for Bio-tech is either non existent or very high P/E's because the companies are so focused on R&D which is the only way to ensure long term profits. Along with the market cap stability in the stock this year, we have seen a little bit of balance sheet stability as well. Cash and assets have increased significantly over the end of 2007 while liabilities have seen a much smaller rise. Our reasons for picking this stock primarily have to do with recent developments in the company coupled with a very small number of shares outstanding. Specifically, BioTime has recently entered into the field of regenerative medicine through their wholly owned subsidiary, Embryome Sciences, Inc. Overall, the stocks decent fundamentals may warrant something a little longer that a short term trade, but we believe the stocks immediate outlook is very positive. |
Business description BioTime, Inc., a biomedical company, engages in the research and development of synthetic plasma expanders, blood volume substitute solutions, and organ preservation solutions for use in surgery, trauma care, organ transplant procedures, and other areas of medicine. Its lead product, Hextend, is a hetastarch-based synthetic blood plasma volume expander designed to treat hypovolemia in surgery for patients with blood loss. The company is also developing PentaLyte, a pentastarch-based synthetic plasma expander for the treatment of hypovolemia in cardiac surgery; HetaCool, a modified formulation of Hextend, which is designed for use at low temperatures; and other synthetic plasma expander solutions to treat acute blood loss that occurs as a result of trauma injuries and during various surgeries. BioTime has an agreement with Summit Pharmaceuticals International Corporation to develop Hextend and PentaLyte in Japan, the People's Republic of China, and Taiwan. The company was founded in 1990 and is headquartered in Emeryville, California. |
| Market Cap: 47.59M Shares Outstanding: 23.79M Float: 17.70M % Held by Insiders: 54.89% |
| BTIM (OTC BB) Year Founded 1990 # of Employees 9 Employees Website www.biotimeinc.com |
| 3 Months Avg. Price: 1.47 1 Month Avg. Price: 1.86 10 Days Avg. Price: 1.91 5 Days Avg. Price: 1.98 |
as of 12/8/08